Navigation Links
Enteris BioPharma Forms Scientific Advisory Board to Enhance Leadership in Oral Delivery of Peptide and Small Molecule Drugs
Date:12/3/2013

antibiotics in worldwide sales, exceeding $1.3 billion in 2012.  He also initiated the Upjohn research program and led the team that discovered linezolid and clinical candidates eperezolid and sutezolid. At Pfizer, he led the early clinical development team for sutezolid, which has completed Phase 2a trials as a potential treatment for MDR M. tuberculosis infections.  Currently the owner of SJ Brickner Consulting, LLC, Dr. Brickner holds an MS and Ph.D. in organic chemistry from Cornell University, and was an NIH postdoctoral fellow at the University of Wisconsin-Madison.  He is author or co-author on 36 peer-reviewed publications and 80 scientific presentations, and is inventor/co-inventor on 23 issued US patents.

Dr. Brickner remarked, "I'm excited to be working with Enteris as a member of its SAB.  Enteris has a proven technology platform for improving oral bioavailability, and it holds significant potential for expanding the utility and market for certain anti-infective drugs that currently have poor oral bioavailability. As a drug discoverer and medicinal chemistry consultant with more than 30 years of experience working on the discovery of new antibiotics, I believe I can bring value to Enteris by sharing my broad anti-infective knowledge and drug-discovery expertise."

Dr. Chernoff is an internationally recognized expert in signal transduction, with particular interest in the regulation of cell proliferation and movement by protein kinases and phosphatases.  Currently the Chief Scientific Officer at the Fox Chase Cancer Center, Dr. Chernoff coordinates and charts the future course of research at the hospital, which he joined in 1991.  A molecular oncologist as well as a board-certified medical oncologist, Dr. Chernoff earned his MD and his Ph.D. in biochemistry in 1984 at Mount Sinai School of Medicine in New York City. He completed his residency in internal medicine at the University Healt
'/>"/>

SOURCE Enteris BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Enteris BioPharma and Nordic BioSciences KeyBioScience Enter Strategic Licensing Agreement to Develop Metabolic Peptides Using Enteris Proprietary Oral Drug Delivery and Manufacturing Platform
2. Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics
3. Therapure Biopharma Inc. has Acquired Plasma Protein Purification Technology From Upfront Chromatography A/S
4. PDL BioPharma to Present at the 25th Annual Piper Jaffray Healthcare Conference
5. UCLA Venture Capital Fund Selects KYTHERA Biopharmaceuticals CEO Keith Leonard for First Annual Entrepreneurial Achievement Award
6. IPO, Earnings & Corporate Developments: Twitter, Vale SA, OCZ Technology Group, Radian Group, Keryx Biopharmaceuticals
7. TransCelerate BioPharma Inc. Launches Second Year Initiatives, Expands Membership and Achieves Milestones for Original Projects
8. Biopharmaceuticals - A Global Market Overview
9. Can-Fite BioPharma to Conduct European Road Show
10. MGB Biopharma to Present at Bio-Europe 2013
11. Sanofi Adopts Genedata Biologics for Integrated Biopharma R&D Process Support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
(Date:12/22/2014)... Memphis, TENN (PRWEB) December 22, 2014 ... with Donor Egg Bank USA , a network ... the country. Through this partnership, patients have fast access ... for in vitro fertilization, IVF . Fertility Associates of ... to offer this fertility treatment option. , Dr. ...
(Date:12/19/2014)... 19, 2014 Charm Sciences is pleased ... the Detection of Aflatoxin M1 in raw commingled milk ... third party validation. The peer reviewed report of the ... Institute for Agricultural and Fisheries Research (ILVO-T&V) has been ... Aflatoxin B1, the most toxic aflatoxin and a known ...
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
Breaking Biology Technology:Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... fight cancer, rheumatoid arthritis, as well as enhance ... CEL-SCI Corporation (NYSE Amex: CVM ) ... 11th annual National Foundation of Infectious Diseases Conference ... L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) vaccine technology ...
... April 27 MannKind Corporation (Nasdaq: MNKD ... on Monday, May 4, 2009.Management of the Company will ... financial results and other Company developments at 4:00 PM ... will be its Chairman and Chief Executive Officer, Alfred ...
... SAN DIEGO, April 27 Cadence Pharmaceuticals, Inc. (Nasdaq: ... clinical trials of its investigational product candidate, Acetavance(TM) (intravenous ... Regional Anesthesia and Pain Medicine (ASRA) 34th Annual Regional ... and at the Society of Hospital Medicine (SHM) Annual ...
Cached Biology Technology:CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease 2CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease 3CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease 4MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 4, 2009 2Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences 2
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... category for the largest human-designed protein, then a team of ... have designed and successfully synthesized a variant of a protein ... It is more than twice the size of the previous ... of Washington in 2003. The synthetic protein, designated FLR, ...
... A study conducted by researchers at the Johns Hopkins ... patterns of drug resistance in malaria-causing parasites taken from ... in human blood samples showed a high prevalence for ... widely used to treat malaria in the region. However, ...
... CHAPEL HILL, N.C. After a heart attack, the portions ... scar tissue. Researchers have long sought ways to avoid this ... its ability to pump blood throughout the body and eventually ... of North Carolina at Chapel Hill School of Medicine shows ...
Cached Biology News:Creation of the largest human-designed protein boosts protein engineering efforts 2Creation of the largest human-designed protein boosts protein engineering efforts 3Contrasting patterns of malaria drug resistance found between humans and mosquitoes 2Scarring a necessary evil to prevent further damage after heart attack 2
... DNA Polymerase is a premium quality recombinant ... thermostable enzyme is suitable for a wide ... highest purity and reproducible performance, each preparation ... quality control assays. NovaTaq DNA Polymerase possesses ...
... cell sorter sets a new standard for ... a revolutionary new design in instrumentation, this ... multicolor analysis. The BD FACSAria instrument is ... fixed-alignment cuvette flow cell. This new ...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Biology Products: